📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Financial Results
Filing Date: 2022-08-03
Accepted: 2022-08-03 07:08:21
Event Type: Financial Results
Event Details:
Regeneron Pharmaceuticals Inc (REGN) Reports Q3 2022 Financial Results
Regeneron Pharmaceuticals Inc (REGN) announced its financial results for the period ending Q3 2022.
Key Financial Highlights:
Revenue: 2857
Net Income: 9.77
EPS: Not disclosed
Cash and equivalents: $13,982
In June 2022, the U.S. Food and Drug Administration (FDA) approved Dupixent as the first biologic medicine for children aged 6 months to 5 years with moderate
severe atopic dermatitis.
In May 2022, the FDA approved Dupixent for adults and adolescents aged 12 years and older with eosinophilic esophagitis (EoE).
targeting TLR9), which is in clinical development for oncology. •Effective July 1, 2022
📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Financial Results
Filing Date: 2022-08-03
Accepted: 2022-08-03 07:08:21
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: